Effect of the Direct Renin Inhibitor Aliskiren on Endothelial Function and Arterial Stiffness in Diabetic Subjects.

Trial Profile

Effect of the Direct Renin Inhibitor Aliskiren on Endothelial Function and Arterial Stiffness in Diabetic Subjects.

Discontinued
Phase of Trial: Phase IV

Latest Information Update: 15 May 2017

At a glance

  • Drugs Aliskiren (Primary)
  • Indications Hypertension
  • Focus Pharmacodynamics
  • Most Recent Events

    • 17 Feb 2012 Actual patient number (27) added as reported by ClinicalTrials.gov.
    • 17 Feb 2012 Actual initiation (Jun 2011) date added as reported by ClinicalTrials.gov.
    • 17 Feb 2012 Planned end date changed from 1 Dec 2012 to 1 Jan 2012 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top